Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma
Advanced Science · 2026
DOI: 10.1002/advs.202519586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Poorvi Subramanian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiological Sciences, Oklahoma State University, Stillwater, Oklahoma, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Cell Plasticity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, Oklahoma Center for the Advancement of Science and Technology, NIH HHS.
Abstract (Originalsprache)
Therapy‐resistant neuroblastoma (NB) reflects a lethal convergence of cellular plasticity and immune escape, yet the molecular drivers remain elusive. Here, we identify retinal degeneration protein 3 (RD3) as a master regulator of NB lineage fidelity and tumor immunogenicity. RD3 loss, induced by therapy, triggers a reprogramming cascade involving epithelial‐mesenchymal transition, pluripotency circuitry, and cancer stem cell enrichment. Mechanistically, RD3 binds to and regulates the promoter activity of SOX2, NANOG, and OCT3/4, as well as regulates the transcription of EMT factors. Concurrently, RD3 deficiency disrupts antigen presentation (MHC I/II, β2M), upregulates immune checkpoints (PDL1, CD276), and activates immune‐suppressive signaling (CD24, CD73, A2AR), fostering an immune‐silent microenvironment. RD3 restoration reverses these transitions, reinstating epithelial identity, differentiation, and immune surveillance. In‐vivo, RD3 modulates immune cell infiltration, activation, and tumor clearance. Mechanistically, RD3 governs a self‐reinforcing axis of cellular identity and immunoediting (by regulating T‐cell cytokine release, activation, and cytotoxic function), positioning it as a critical checkpoint in NB evolution. These findings establish RD3 as a dual‐function molecular switch and nominate RD3‐targeted strategies to re‐sensitize high‐risk NB to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiological Sciences, Oklahoma State University, Stillwater, Oklahoma, USA.
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
ORCID-Profile: Natarajan Aravindan
Förderung
- U.S. Department of Defense
- Oklahoma Center for the Advancement of Science and Technology
- NIH HHS
- National Cancer Institute Cancer Center
- Oklahoma Tobacco Settlement Endowment Trust
- Kerr Foundation
- National Institutes of Health
Zitieren
APA
Subramanian, P., Mohanvelu, S., Aravindan, S., Jahir Hussain, A. P., Narayanan, S., Salim, S., Periyasamy, L., & Aravindan, N. (2026). Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. Advanced Science. https://doi.org/10.1002/advs.202519586
Vancouver
Subramanian P, Mohanvelu S, Aravindan S, Jahir Hussain AP, Narayanan S, Salim S, et al. Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma. Advanced Science. 2026. doi:10.1002/advs.202519586
BibTeX
@article{Subramanian2026,
author = {Subramanian, Poorvi and Mohanvelu, Sreenidhi and Aravindan, Sheeja and Jahir Hussain, Afsana Parveen and Narayanan, Sivasubramani and Salim, Sabir and Periyasamy, Loganayaki and Aravindan, Natarajan},
title = {Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202519586}
}
EUVIMED